4th Quarter - Report

EXPRESS SCRIPTS, INC. for EXPRESS SCRIPTS, INC.

Firm
Client
Income
—
Expenses
$840,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Implementation of tax provisions of the ACA and tax reform policies.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
SERGIO SANTIVIAGO —

Contacted: Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Food & Drug Administration (FDA); Government Accountability Office (GAO); Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); White House Office; Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL); Congressional Budget Office (CBO); SENATE; Office of Personnel Management (OPM); Medicare Payment Advisory Commission (MedPAC)

Health Issues HCR

Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues, including biosimilars. Reforms to Medicaid and Exchange markets.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
SERGIO SANTIVIAGO —

Contacted: Congressional Budget Office (CBO); Internal Revenue Service (IRS); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); White House Office; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Government Accountability Office (GAO); Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); Labor, Dept of (DOL); Office of Personnel Management (OPM); Medicare Payment Advisory Commission (MedPAC); SENATE

Defense DEF

Pharmacy issues related to the annual defense authorization and implementation of the 2018 NDAA.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
MICHAEL DONNELLY —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
LISA CHRISTINE LE GETTE —
SERGIO SANTIVIAGO —

Contacted: SENATE; Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); White House Office; Labor, Dept of (DOL); Congressional Budget Office (CBO); Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Executive Office of the President (EOP); Medicare Payment Advisory Commission (MedPAC); Office of Personnel Management (OPM)

Medicare/Medicaid MMM

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
LISA CHRISTINE LE GETTE —
SERGIO SANTIVIAGO —

Contacted: HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); SENATE; Medicare Payment Advisory Commission (MedPAC); Executive Office of the President (EOP); Labor, Dept of (DOL); Congressional Budget Office (CBO); Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Government Accountability Office (GAO); Office of Personnel Management (OPM); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); White House Office; Internal Revenue Service (IRS)

Bills named: H.R. 1939 (115th), H.R. 1920 (115th)

Pharmacy PHA

Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.

LobbyistCovered position, as disclosed
CHRISTOPHER DAVIS —
JONAH C HOUTS —
EMILY A KATZ —
GARY J KLINE —
LISA CHRISTINE LE GETTE —
SERGIO SANTIVIAGO —

Contacted: Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Federal Trade Commission (FTC); Labor, Dept of (DOL); Health Resources & Services Administration (HRSA); Government Accountability Office (GAO); White House Office; Congressional Budget Office (CBO); Office of Personnel Management (OPM); Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 6 (115th), H.R. 2025 (115th), H.R. 1854 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.